Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.4K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.4K
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

250
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
250
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

179
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
179
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

74
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
74
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

91
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
91
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

104
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
104

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CAFETERIA SURVIVAL A FIELD GUIDE.

Diabetes self-management·2018
Same author

XII Diabetes Myths Debunked.

Diabetes self-management·2018
Same author

More Consumer Diabetes Products Using Technology to Get--and Stay--Connected.

Diabetes self-management·2016
Same author

ALL IN A DAY'S WORK.

Diabetes self-management·2015
Same author

The symptomless condition.

Diabetes self-management·2015
Same author

Fear of fat. A fresh look at an old enemy.

Diabetes self-management·2015

Related Experiment Video

Updated: Mar 19, 2026

Novel Photoacoustic Microscopy and Optical Coherence Tomography Dual-modality Chorioretinal Imaging in Living Rabbit Eyes
09:20

Novel Photoacoustic Microscopy and Optical Coherence Tomography Dual-modality Chorioretinal Imaging in Living Rabbit Eyes

Published on: February 8, 2018

11.5K

Coming Soon to a Pharmacy Near You.

Wil Dubois

    Diabetes Self-Management
    |June 14, 2016
    PubMed
    Summary

    New FDA-approved drugs offer cheaper insulin and advanced glucose control. These innovations aim to lower blood sugar and repair damage, with more treatments expected annually.

    Area of Science:

    • Pharmacology and Therapeutics
    • Endocrinology
    • Cardiovascular Medicine

    Background:

    • Recent Food and Drug Administration (FDA) approvals include novel therapeutic agents.
    • These approvals address critical areas such as diabetes management and cardiovascular health.
    • Emerging treatments present significant cost considerations, with some lipid-lowering drugs priced comparably to cancer therapies.

    Purpose of the Study:

    • To summarize recent FDA approvals impacting metabolic and cardiovascular diseases.
    • To highlight new therapeutic options for blood glucose control and lipid management.
    • To contextualize the cost and innovation landscape of newly approved pharmaceuticals.

    Main Methods:

    • Review of recent FDA drug approval announcements.

    More Related Videos

    Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
    06:08

    Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

    Published on: March 11, 2017

    11.2K
    Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
    10:33

    Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

    Published on: December 17, 2021

    3.3K

    Related Experiment Videos

    Last Updated: Mar 19, 2026

    Novel Photoacoustic Microscopy and Optical Coherence Tomography Dual-modality Chorioretinal Imaging in Living Rabbit Eyes
    09:20

    Novel Photoacoustic Microscopy and Optical Coherence Tomography Dual-modality Chorioretinal Imaging in Living Rabbit Eyes

    Published on: February 8, 2018

    11.5K
    Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
    06:08

    Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

    Published on: March 11, 2017

    11.2K
    Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
    10:33

    Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

    Published on: December 17, 2021

    3.3K
  • Analysis of drug classes, therapeutic indications, and pricing information.
  • Synthesis of information on novel mechanisms of action for glucose-lowering and lipid-modifying agents.

    • Main Results:

    • Introduction of insulin biosimilars offering a more affordable alternative.
    • Approval of novel agents for blood glucose reduction with advanced mechanisms.
    • Launch of lipid-lowering drugs with high price points, comparable to oncology medications.
    • A robust pipeline of hundreds of potential new drugs, with an estimated 1-2 FDA approvals per year.

    Conclusions:

    • Recent FDA approvals signify advancements in managing diabetes and dyslipidemia.
    • The availability of cheaper insulin biosimilars is a significant development for patient access.
    • High-cost novel therapies necessitate careful consideration of economic impact and value.
    • The pharmaceutical pipeline suggests continued innovation in metabolic and cardiovascular disease treatment.